Finnish biotech startup Nadmed said on Thursday that it has raised €3.5 million ($3.9 million) in a Series A financing round.​

Oncocyte Corporation, a company specializing in in vitro and in vivo diagnostic substances, has regained compliance with Nasdaq's listing rules regarding board and audit committee composition. The notice of compliance was received by the company on Monday, following a period of noncompliance caused by the passing of director Alfred D. Kingsley on April 25, 2024.

Element Biosciences said Thursday that it has raised more than $277 million in Series D funding.

Illumina, Inc. (NASDAQ: ILMN) today announced the successful completion of the spin-off of GRAIL. This milestone follows the company's previously announced plans to divest GRAIL, and GRAIL is now a public and independent company. GRAIL will begin regular way trading on Nasdaq on Tuesday, June 25 under the ticker symbol "GRAL." Illumina will continue to trade on Nasdaq under the ticker symbol "ILMN."

Cleveland Diagnostics, Inc., a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers announced the closing of over $75M in growth capital financing. The financing was led by Novo Holdings, a leading global life sciences investor, responsible for managing the assets of the Novo Nordisk Foundation, along with participation from existing investors as well as a credit facility from Symbiotic Capital. The financing will accelerate Cleveland Diagnostics’ commercial and corporate development goals.

Tome Biosciences, a new genome editing company, emerged from stealth on Tuesday and announced that it has raised $213 million between its Series A and B financing rounds.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Shanghai Kirgen, a leading domestic manufacturer of high-end laboratory consumables and new materials, has just announced that it has completed a new round of financing of nearly 100 million Yuan.

Recently, WillingMed Technology(Beijing) Co., Ltd. announced the completion of a CNY hundreds of millions Series B financing round.

In March 2023, Cygnus received another round of Series C+ financing of hundreds of millions of RMB, led by Source Capital, and followed by Jianxin Equity, Yizhuang State Investment, Fangzhenghesheng, and Hetang Venture Capital.